FDA warned goodimmuno.com for selling unapproved, misbranded tramadol and diazepam online without prescriptions.
What happened
FDA reviewed the website www.goodimmuno.com and observed that it introduced unapproved and misbranded opioid and benzodiazepine drugs into interstate commerce. The site offered tramadol 50mg and diazepam 10mg to U.S. consumers without requiring a prescription, and FDA said the labeling lacked adequate directions for use.
What FDA found
The website sells tramadol and diazepam as new drugs without FDA-approved applications.
FD&C Act sections 301(d), 505(a) [21 U.S.C. §§ 331(d), 355(a)]The drug labeling lacks adequate directions for safe use by a layperson.
FD&C Act section 502(f)(1) [21 U.S.C. § 352(f)(1)]; 21 CFR 201.5The website offers prescription drugs without requiring a prescription, which misbrands them.
FD&C Act sections 503(b)(1), 301(k) [21 U.S.C. §§ 353(b)(1), 331(k)]
What FDA wants
FDA asks goodimmuno.com to stop offering any unapproved and misbranded drugs to U.S. consumers and to reply in writing within 15 working days with corrective steps and documentation.
Who should pay attention
- online pharmacies and websites selling prescription drugs
- platforms, hosts, and payment providers serving online drug sellers
- regulatory teams at companies whose prescription products appear on unauthorized sites
This is a summary. Read the original letter on fda.gov.